DRI Healthcare Trust (TSE:DHT.UN) Receives C$17.94 Consensus PT from Brokerages

Shares of DRI Healthcare Trust (TSE:DHT.UN) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is C$17.94.

A number of research firms recently commented on DHT.UN. Scotiabank boosted their price target on DRI Healthcare Trust from C$21.00 to C$22.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Raymond James reduced their price objective on DRI Healthcare Trust from C$23.00 to C$22.00 in a research report on Wednesday, November 13th. Finally, CIBC dropped their price target on shares of DRI Healthcare Trust from C$19.50 to C$18.00 and set an “outperform” rating for the company in a research note on Thursday, December 12th.

DRI Healthcare Trust Trading Up 1.5 %

Shares of DHT.UN opened at C$12.00 on Monday. The firm’s 50-day simple moving average is C$12.85 and its 200 day simple moving average is C$13.00. DRI Healthcare Trust has a 52 week low of C$10.39 and a 52 week high of C$17.43.

About DRI Healthcare Trust

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.